The sudden resignation of Peter Marks, M.D., Ph.D., from the FDA branch that regulates biological products for humans ...
Amid a dramatic reshaping of the federal healthcare apparatus, the FDA has named an acting leader of its Center for Biologics Evaluation and Research. | Amid a dramatic reshaping of the federal ...
Following the dramatic late-night resignation of Peter Marks last Friday, Steele, a senior advisor to the division, takes the ...
WASHINGTON − The Supreme Court on Wednesday unanimously overturned a lower court’s decision that the Food and Drug Administration incorrectly blocked companies from selling fruit- and candy ...
The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on track to be cleared until Tuesday afternoon, a person familiar with the ...
WASHINGTON, April 2 (Reuters) - The U.S. Supreme Court on Wednesday largely backed the U.S. Food and Drug Administration's refusal to let two e-cigarette companies sell flavored vape products that ...
Amy Comstock Rick joined the FDA last November, and she not only survived the widespread staff cuts last week, she’s one of only a handful … Get free access to a limited number of articles, ...
A drug bust quickly led to high-speed chase and pursuit through the woods in the Hazleton area. On Tuesday, the Hazleton City Narcotics Unit received a tip from the Drug Enforcement Agency (DEA ...
Researchers say they have discovered a new class of antibiotics that could treat drug-resistant bacteria, the first to reach the market in nearly three decades. The new molecule, called ...
She was speaking after two men were convicted of being involved in the killing of a 37-year-old drug "runner" Dean Fountaine, from Leighton Buzzard. Peter Janoski, 44, has been found guilty of murder ...
Drug screening is the process by which potential drugs are identified and optimized before selection of a candidate drug to progress to clinical trials. It can involve screening large libraries of ...
This latest estimate from the Tufts Center for Drug Development of the cost of developing a new chemical entity to the point of submission for regulatory approval has already been widely debated.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback